- Home
- FLNC vs IMCR Comparison
FLNC vs IMCR Comparison
Compare FLNC & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- IMCR
- Stock Information
- Founded
- FLNC 2018
- IMCR 2008
- Country
- FLNC United States
- IMCR United Kingdom
- Employees
- FLNC N/A
- IMCR N/A
- Industry
- FLNC Industrial Machinery/Components
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FLNC Miscellaneous
- IMCR Health Care
- Exchange
- FLNC Nasdaq
- IMCR Nasdaq
- Market Cap
- FLNC 969.5M
- IMCR 1.8B
- IPO Year
- FLNC 2021
- IMCR 2021
- Fundamental
- Price
- FLNC $7.50
- IMCR $33.81
- Analyst Decision
- FLNC Hold
- IMCR Buy
- Analyst Count
- FLNC 19
- IMCR 8
- Target Price
- FLNC $8.47
- IMCR $57.00
- AVG Volume (30 Days)
- FLNC 4.2M
- IMCR 270.5K
- Earning Date
- FLNC 08-11-2025
- IMCR 11-05-2025
- Dividend Yield
- FLNC N/A
- IMCR N/A
- EPS Growth
- FLNC N/A
- IMCR N/A
- EPS
- FLNC N/A
- IMCR N/A
- Revenue
- FLNC $2,449,087,000.00
- IMCR $356,145,000.00
- Revenue This Year
- FLNC N/A
- IMCR $31.83
- Revenue Next Year
- FLNC $21.59
- IMCR $8.50
- P/E Ratio
- FLNC N/A
- IMCR N/A
- Revenue Growth
- FLNC 14.26
- IMCR 26.78
- 52 Week Low
- FLNC $3.46
- IMCR $23.15
- 52 Week High
- FLNC $24.00
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- FLNC 51.24
- IMCR 46.61
- Support Level
- FLNC $6.60
- IMCR $35.33
- Resistance Level
- FLNC $7.60
- IMCR $36.76
- Average True Range (ATR)
- FLNC 0.46
- IMCR 1.43
- MACD
- FLNC 0.05
- IMCR 0.00
- Stochastic Oscillator
- FLNC 52.89
- IMCR 30.79
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.